Resolving Conflicting Data on Expression of the Tn Antigen and Implications for Clinical Trials with Cancer Vaccines

Overview

Journal Mol Cancer Ther

Date 2009 Apr 18

PMID 19372570

Citations 34

Authors

Qian Li

Miriam R Anver

Donna O Butcher

Jeffrey C Gildersleeve

Affiliations

Soon will be listed here.

Abstract

The tumor-associated Tn antigen has been investigated extensively as a biomarker and therapeutic target. Cancer vaccines containing the Tn antigen as a single tumor antigen or as a component of a polyvalent vaccine have progressed into phase I and II clinical trials. One major focus of Tn-based vaccines is the treatment of prostate cancer patients. Although expression of the antigen on prostate tumors is a critical prerequisite, previous reports investigating Tn expression in prostate tumors have produced conflicting results. Using a combination of immunohistochemistry and carbohydrate microarray profiling, we show that only 4% to 26% of prostate tumors express the Tn antigen. Based on our results, the majority of prostate cancer patients do not express the appropriate antigen. Therefore, efforts to preselect the subset of prostate cancer patients with Tn-positive tumors or apply Tn vaccines to other cancers with higher rates of antigen expression could significantly improve clinical response rates. Because conflicting information on carbohydrate expression is a general problem for the field, the approach described in this article of analyzing antigen expression with multiple antibodies and using carbohydrate microarray profiles to interpret the results will be useful for the development of other carbohydrate-based cancer vaccines and diagnostics.

Citing Articles

Detection of Tn-antigen in breast and prostate cancer models by VVL-labeled red dye-doped nanoparticles.

Verhassel A, Kimani M, Gidwani K, Sandholm J, Gawlitza K, Rurack K Nanomedicine (Lond). 2024; 19(29):2463-2478.

PMID: 39382009 PMC: 11520574. DOI: 10.1080/17435889.2024.2405454.

Tn antigen interactions of macrophage galactose-type lectin (MGL) in immune function and disease.

Tumoglu B, Keelaghan A, Avci F Glycobiology. 2023; 33(11):879-887.

PMID: 37847609 PMC: 10859631. DOI: 10.1093/glycob/cwad083.

Targeting altered glycosylation in secreted tumor glycoproteins for broad cancer detection.

Kudelka M, Gu W, Matsumoto Y, Ju T, Barnes Ii R, Kardish R Glycobiology. 2023; 33(7):567-578.

PMID: 37216646 PMC: 10426321. DOI: 10.1093/glycob/cwad035.

Upregulation of GALNT7 in prostate cancer modifies O-glycosylation and promotes tumour growth.

Scott E, Hodgson K, Calle B, Turner H, Cheung K, Bermudez A Oncogene. 2023; 42(12):926-937.

PMID: 36725887 PMC: 10020086. DOI: 10.1038/s41388-023-02604-x.

Development of a GalNAc-Tyrosine-Specific Monoclonal Antibody and Detection of Tyrosine -GalNAcylation in Numerous Human Tissues and Cell Lines.

Xia L, Bellomo T, Gibadullin R, Congdon M, Edmondson E, Li M J Am Chem Soc. 2022; 144(36):16410-16422.

PMID: 36054098 PMC: 10655760. DOI: 10.1021/jacs.2c04477.

References

Sakuraba H, Matsuzawa F, Aikawa S, Doi H, Kotani M, Nakada H . Structural and immunocytochemical studies on alpha-N-acetylgalactosaminidase deficiency (Schindler/Kanzaki disease). J Hum Genet. 2003; 49(1):1-8. DOI: 10.1007/s10038-003-0098-z. View

Cao Y, Karsten U, Liebrich W, Haensch W, Springer G, Schlag P . Expression of Thomsen-Friedenreich-related antigens in primary and metastatic colorectal carcinomas. A reevaluation. Cancer. 1995; 76(10):1700-8. DOI: 10.1002/1097-0142(19951115)76:10<1700::aid-cncr2820761005>3.0.co;2-z. View

Springer G, Desai P, Banatwala I . Blood group MN antigens and precursors in normal and malignant human breast glandular tissue. J Natl Cancer Inst. 1975; 54(2):335-9. View

Cipolla L, Rescigno M, Leone A, Peri F, La Ferla B, Nicotra F . Novel Tn antigen-containing neoglycopeptides: synthesis and evaluation as anti tumor vaccines. Bioorg Med Chem. 2002; 10(5):1639-46. DOI: 10.1016/s0968-0896(01)00433-3. View

Zhang Y, Iwasaki H, Wang H, Kudo T, Kalka T, Hennet T . Cloning and characterization of a new human UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase, designated pp-GalNAc-T13, that is specifically expressed in neurons and synthesizes GalNAc alpha-serine/threonine antigen. J Biol Chem. 2002; 278(1):573-84. DOI: 10.1074/jbc.M203094200. View

Springer G . T and Tn, general carcinoma autoantigens. Science. 1984; 224(4654):1198-206. DOI: 10.1126/science.6729450. View

Keding S, Danishefsky S . Prospects for total synthesis: a vision for a totally synthetic vaccine targeting epithelial tumors. Proc Natl Acad Sci U S A. 2004; 101(33):11937-42. PMC: 514412. DOI: 10.1073/pnas.0401894101. View

Dziadek S, Hobel A, Schmitt E, Kunz H . A fully synthetic vaccine consisting of a tumor-associated glycopeptide antigen and a T-cell epitope for the induction of a highly specific humoral immune response. Angew Chem Int Ed Engl. 2005; 44(46):7630-5. DOI: 10.1002/anie.200501594. View

Slovin S, Ragupathi G, Fernandez C, Diani M, Jefferson M, Wilton A . A polyvalent vaccine for high-risk prostate patients: "are more antigens better?". Cancer Immunol Immunother. 2007; 56(12):1921-30. PMC: 11030789. DOI: 10.1007/s00262-007-0335-y. View

10.

Oyelaran O, Gildersleeve J . Application of carbohydrate array technology to antigen discovery and vaccine development. Expert Rev Vaccines. 2008; 6(6):957-69. DOI: 10.1586/14760584.6.6.957. View

11.

Zhang S, Zhang H, Reuter V, Slovin S, Scher H, Livingston P . Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers. Clin Cancer Res. 1998; 4(2):295-302. View

12.

Hansen J, Nielsen C, Arendrup M, Olofsson S, Mathiesen L, Nielsen J . Broadly neutralizing antibodies targeted to mucin-type carbohydrate epitopes of human immunodeficiency virus. J Virol. 1991; 65(12):6461-7. PMC: 250685. DOI: 10.1128/JVI.65.12.6461-6467.1991. View

13.

Manimala J, Li Z, Jain A, VedBrat S, Gildersleeve J . Carbohydrate array analysis of anti-Tn antibodies and lectins reveals unexpected specificities: implications for diagnostic and vaccine development. Chembiochem. 2005; 6(12):2229-41. DOI: 10.1002/cbic.200500165. View

14.

Takahashi H, Metoki R, Hakomori S . Immunoglobulin G3 monoclonal antibody directed to Tn antigen (tumor-associated alpha-N-acetylgalactosaminyl epitope) that does not cross-react with blood group A antigen. Cancer Res. 1988; 48(15):4361-7. View

15.

OBoyle K, Wright K . Anti-Tn human monoclonal antibodies generated following active immunization with partially desialylated ovine submaxillary mucin. Hum Antibodies Hybridomas. 1994; 5(1-2):25-31. View

16.

Springer G . Immunoreactive T and Tn epitopes in cancer diagnosis, prognosis, and immunotherapy. J Mol Med (Berl). 1997; 75(8):594-602. DOI: 10.1007/s001090050144. View

17.

Gildersleeve J, Oyelaran O, Simpson J, Allred B . Improved procedure for direct coupling of carbohydrates to proteins via reductive amination. Bioconjug Chem. 2008; 19(7):1485-90. PMC: 2629553. DOI: 10.1021/bc800153t. View

18.

Itzkowitz S, Yuan M, Montgomery C, Kjeldsen T, Takahashi H, Bigbee W . Expression of Tn, sialosyl-Tn, and T antigens in human colon cancer. Cancer Res. 1989; 49(1):197-204. View

19.

Slovin S, Ragupathi G, Musselli C, Olkiewicz K, Verbel D, Kuduk S . Fully synthetic carbohydrate-based vaccines in biochemically relapsed prostate cancer: clinical trial results with alpha-N-acetylgalactosamine-O-serine/threonine conjugate vaccine. J Clin Oncol. 2003; 21(23):4292-8. DOI: 10.1200/JCO.2003.04.112. View

20.

Giuffre G, Vitarelli E, Tuccari G, Ponz de Leon M, Barresi G . Detection of Tn, sialosyl-Tn and T antigens in hereditary nonpolyposis colorectal cancer. Virchows Arch. 1996; 429(6):345-52. DOI: 10.1007/BF00198438. View